ICICI Bank on Pace for Largest Percent Increase Since March 2022 — Data Talk
ICICI Bank Limited Sponsored ADR (IBN) is currently at $24.24, up $1.27 or 5.51%
--Would be highest close since Aug. 1, 2023, when it closed at $24.50
--On pace for largest percent increase since March 9, 2022, when it rose 6.55%
--Currently up three of the past four days
--Currently up two consecutive days; up 9.31% over this period
--Best two day stretch since the two days ending Feb. 2, 2021, when it rose 14.83%
--Up 10.71% year-to-date
--Down 1.72% from its all-time closing high of $24.66 on July 26, 2023
--Up 6.01% from 52 weeks ago (Dec. 5, 2022), when it closed at $22.86
--Down 1.72% from its 52-week closing high of $24.66 on July 26, 2023
--Up 22.4% from its 52-week closing low of $19.80 on March 15, 2023
--Traded as high as $24.30; highest intraday level since Aug. 2, 2023, when it hit $24.31
--Up 5.79% at today's intraday high; largest intraday percent increase since March 9, 2022, when it rose as much as 6.96%
All data as of 2:11:59 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
December 04, 2023 14:31 ET (19:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?